IN SILICO HEAD-TO-HEAD COMPARISON OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC IN TYPE 1 DIABETES

被引：0

作者：

Visentin, R. ^{[1
]}

Schiavon, M. ^{[1
]}

Giegerich, C. ^{[2
]}

Sieber, J. ^{[2
]}

Man, C. Dalla ^{[1
]}

Cobelli, C. ^{[1
]}

Klabunde, T. ^{[2
]}

机构：

[1] Univ Padua, Dept Informat Engn, Padua, Italy

[2] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany

来源：

DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

037

引用

页码：A18 / A18

页数：1

共 50 条

[31] Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus [J].

Hannah A. Blair ;

Gillian M. Keating .

Drugs, 2016, 76 :363-374

[32] Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia? [J].

Buscemi, Silvio ;

Randazzo, Cristiana ;

Buscemi, Carola .

JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) :1595-1596

[33] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus [J].

Goldman, Jennifer ;

White, John R., Jr. .

ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) :1153-1161

[34] Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study) [J].

Moser, Othmar ;

Mueller, Alexander ;

Aberer, Felix ;

Aziz, Faisal ;

Kojzar, Harald ;

Sourij, Caren ;

Obermayer, Anna ;

Abbas, Farah ;

Birnbaumer, Philipp ;

Lenz, Jacqueline ;

Mursic, Ines ;

Sternad, Christoph ;

Hoenger, Lukas ;

Ziko, Haris ;

Pferschy, Peter N. ;

Tripolt, Norbert ;

Sourij, Harald .

DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (03) :161-168

[35] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes [J].

Kovatchev, B. ;

Meng, Z. ;

Breton, M. ;

Leroy, B. ;

Cali, A. ;

Perfetti, R. .

DIABETOLOGIA, 2017, 60 :S36-S37

[36] Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing? [J].

Heise, Tim ;

Heckermann, Sascha ;

DeVries, J. Hans .

DIABETES OBESITY & METABOLISM, 2018, 20 (09) :2051-2056

[37] A comparison of Insulin Glargine U300 and Insulin Degludec around spontaneous exercise sessions in people with type 1 diabetes - the ULTRAFLEXI-1 study [J].

Moser, Othmar ;

Mueller, Alexander ;

Aberer, Felix ;

Aziz, Faisal ;

Kojzar, Harald ;

Sourij, Caren ;

Obermayer, Anna ;

Abbas, Farah ;

Birnbaumer, Philipp ;

Eckstein, Max ;

Hoenger, Lukas ;

Lenz, Jaqueline ;

Mursic, Ines ;

Sternad, Christoph ;

Weber, Barbara ;

Zanker, Matthias ;

Ziko, Haris ;

Pferschy, Peter ;

Tripolt, Norbert ;

Sourij, Harald .

WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 4) :251-251

[38] Type 2 Diabetes: Direct Comparison between Insulin Glargine and Insulin Degludec [J].

Lichert, Frank .

DIABETOLOGIE UND STOFFWECHSEL, 2018, 13 (06) :546-546

[39] Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes [J].

Heise, Tim ;

Norskov, Marianne ;

Nosek, Leszek ;

Kaplan, Kadriye ;

Famulla, Susanne ;

Haahr, Hanne L. .

DIABETES OBESITY & METABOLISM, 2017, 19 (07) :1032-1039

[40] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes [J].

Kovatchev, Boris ;

Meng, Zhaoling ;

Cali, Anna M. G. ;

Perfetti, Riccardo ;

Breton, Marc D. .

DIABETES THERAPY, 2020, 11 (06) :1293-1302

← 1 2 3 4 5 →